BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18524988)

  • 1. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia.
    Dulucq S; Bouchet S; Turcq B; Lippert E; Etienne G; Reiffers J; Molimard M; Krajinovic M; Mahon FX
    Blood; 2008 Sep; 112(5):2024-7. PubMed ID: 18524988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
    Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
    Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.
    Deenik W; van der Holt B; Janssen JJ; Chu IW; Valk PJ; Ossenkoppele GJ; van der Heiden IP; Sonneveld P; van Schaik RH; Cornelissen JJ
    Blood; 2010 Dec; 116(26):6144-5; author reply 6145-6. PubMed ID: 21183698
    [No Abstract]   [Full Text] [Related]  

  • 4. Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia.
    Ni LN; Li JY; Miao KR; Qiao C; Zhang SJ; Qiu HR; Qian SX
    Med Oncol; 2011 Mar; 28(1):265-9. PubMed ID: 20204543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.
    Ali MA; Elsalakawy WA
    Med Oncol; 2014 Nov; 31(11):279. PubMed ID: 25301112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients.
    Elghannam DM; Ibrahim L; Ebrahim MA; Azmy E; Hakem H
    Hematology; 2014 Apr; 19(3):123-8. PubMed ID: 23683876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
    Kim DH; Sriharsha L; Xu W; Kamel-Reid S; Liu X; Siminovitch K; Messner HA; Lipton JH
    Clin Cancer Res; 2009 Jul; 15(14):4750-8. PubMed ID: 19584153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.
    Angelini S; Soverini S; Ravegnini G; Barnett M; Turrini E; Thornquist M; Pane F; Hughes TP; White DL; Radich J; Kim DW; Saglio G; Cilloni D; Iacobucci I; Perini G; Woodman R; Cantelli-Forti G; Baccarani M; Hrelia P; Martinelli G
    Haematologica; 2013 Feb; 98(2):193-200. PubMed ID: 22875622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
    Seong SJ; Lim M; Sohn SK; Moon JH; Oh SJ; Kim BS; Ryoo HM; Chung JS; Joo YD; Bang SM; Jung CW; Kim DH; Park SY; Yoon SS; Kim I; Lee HG; Won JH; Min YH; Cheong JW; Park JS; Eom KS; Hyun MS; Kim MK; Kim H; Park MR; Park J; Kim CS; Kim HJ; Kim YK; Park EK; Zang DY; Jo DY; Lee HW; Yoon YR
    Ann Oncol; 2013 Mar; 24(3):756-60. PubMed ID: 23117072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.
    Singh O; Chan JY; Lin K; Heng CC; Chowbay B
    PLoS One; 2012; 7(12):e51771. PubMed ID: 23272163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular study of ABCB1 gene and its correlation with imatinib response in chronic myeloid leukemia.
    Ben Hassine I; Gharbi H; Soltani I; Ben Hadj Othman H; Farrah A; Amouri H; Teber M; Ghedira H; Ben Youssef Y; Safra I; Abbes S; Menif S
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):829-839. PubMed ID: 28836054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
    Vivona D; Bueno CT; Lima LT; Hirata RD; Hirata MH; Luchessi AD; Zanichelli MA; Chiattone CS; Guerra-Shinohara EM
    Blood Cells Mol Dis; 2012 Feb; 48(2):132-6. PubMed ID: 22134106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis.
    Zu B; Li Y; Wang X; He D; Huang Z; Feng W
    Pharmacogenomics; 2014 Apr; 15(5):667-77. PubMed ID: 24798723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Instability of mRNA expression signatures of drug transporters in chronic myeloid leukemia patients resistant to imatinib.
    Gromicho M; Magalhães M; Torres F; Dinis J; Fernandes AR; Rendeiro P; Tavares P; Laires A; Rueff J; Sebastião Rodrigues A
    Oncol Rep; 2013 Feb; 29(2):741-50. PubMed ID: 23229016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Harivenkatesh N; Kumar L; Bakhshi S; Sharma A; Kabra M; Velpandian T; Gogia A; Shastri SS; Gupta YK
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28367681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemia.
    Vine J; Cohen SB; Ruchlemer R; Goldschmidt N; Levin M; Libster D; Gural A; Gatt ME; Lavie D; Ben-Yehuda D; Rund D
    Leuk Lymphoma; 2014 Nov; 55(11):2525-31. PubMed ID: 24524306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of ABCC1 and ABCC2 genotypes and haplotypes in mediating imatinib resistance among chronic myeloid leukaemia patients.
    Au A; Baba AA; Azlan H; Norsa'adah B; Ankathil R
    J Clin Pharm Ther; 2014 Dec; 39(6):685-90. PubMed ID: 25060527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients.
    Zhong JS; Meng FY; Xu D; Zhou HS; Dai M
    Acta Haematol; 2012; 127(4):221-7. PubMed ID: 22473087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response.
    Mohammadi F; Shafiei M; Assad D; Rostami G; Hamid M; Foroughmand AM
    Iran Biomed J; 2021 Jan; 25(1):54-61. PubMed ID: 33129240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.